CAR-T cell therapy (chimeric antigen receptor T-cell therapy) represents an innovative adoptive immunotherapy approach for Alzheimer's disease (AD) that engineers patient's own T cells to recognize and eliminate pathological proteins in the brain. Unlike CAR-A therapy which engineers astrocytes, CAR-T therapy leverages the cytotoxic capabilities of T lymphocytes to target amyloid-β plaques, tau tangles, or other disease-relevant targets.
Alzheimer's disease is characterized by accumulation of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles, leading to progressive neurodegeneration and cognitive decline. While passive immunotherapy with monoclonal antibodies like lecanemab and donanemab has shown clinical benefit, CAR-T therapy offers a potentially more potent and sustained approach by engineering the patient's own immune cells[1][2].
CAR-T therapy has revolutionized oncology, particularly for B-cell malignancies, with FDA-approved therapies like tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). Translating this success to neurodegenerative diseases presents unique challenges related to blood-brain barrier penetration, target selection, and neurotoxicity risks[3].
CAR-T therapy for AD involves engineering a patient's T cells to express chimeric antigen receptors specific for disease-related targets:
The CAR construct consists of three main components:
Once infused, CAR-T cells:
Choosing the right target is critical for CAR-T therapy efficacy and safety:
| Target | Rationale | Development Stage | Key Considerations |
|---|---|---|---|
| Amyloid-β | Core pathological driver of AD | Preclinical | Plaque clearance demonstrated; risk of off-target effects |
| Tau | Correlates with cognitive decline | Preclinical | Intracellular target; may require different CAR design |
| BACE1 | Key amyloid-generating enzyme | Preclinical | Enzyme inhibition reduces Aβ production |
| APP | Source of amyloid-beta | Preclinical | Requires precise epitope selection |
CAR-T cells targeting Aβ are designed to recognize various forms of the protein:
The 2020 study by Haile et al. demonstrated proof-of-concept for Aβ-targeting CAR-T cells in preclinical models, showing plaque reduction and improved cognitive outcomes[1:1].
Tau pathology correlates more closely with cognitive decline than amyloid burden. CAR-T cells targeting tau face the challenge of an intracellular target, requiring:
BACE1 (β-secretase 1) is the rate-limiting enzyme in amyloid-β production. CAR-T cells targeting BACE1-expressing cells could:
| Feature | CAR-T Therapy | CAR-A Therapy |
|---|---|---|
| Cell Type | T lymphocytes | Astrocytes |
| Mechanism | Cytotoxic killing | Phagocytosis + anti-inflammatory |
| Origin | Blood-derived | Brain-resident |
| Delivery | IV or intrathecal | AAV gene therapy |
| Duration | Potential long-term memory | Sustained expression |
| CRS Risk | Higher | Lower |
| Neurotoxicity | ICANS risk | Not well characterized |
| Preclinical Data | Limited | Recent Science 2026 paper |
CAR-T and CAR-A therapies could potentially be combined:
| Risk | Mitigation |
|---|---|
| Cytokine release syndrome | Lower cell doses, preconditioning |
| Neurotoxicity (ICANS) | Graded dosing, safety switches (iCaspase9) |
| On-target off-tumor | Careful epitope selection, conditional CARs |
| Infection risk | Monitoring, prophylactic antibiotics |
Patients may require lymphodepletion prior to CAR-T infusion:
| Phase | Primary Endpoints | Duration |
|---|---|---|
| Phase I | Safety, MTD | 1-2 years |
| Phase II | Cognitive endpoints, biomarker changes | 2-3 years |
| Phase III | Clinical cognition, function | 3+ years |
Key biomarkers to track:
Future development may enable:
Haile M, et al. CAR-T cell therapy for Alzheimer's disease. Molecular Therapy. 2020. ↩︎ ↩︎
ALZFORUM Therapeutics Database. Amyloid-Related immunotherapies. 2026. ↩︎
Roth TL, et al. Engineering CAR-T cells for neurodegenerative disease. Science Translational Medicine. 2023. ↩︎ ↩︎ ↩︎